Mcl1-IN-8 |
| Catalog No.GC38811 |
Mcl1-IN-8 (Composé 8) est un inhibiteur d'interface Mcl-1-PUMA actif par voie orale, avec un Ki de 0,3 μM. Mcl1-IN-8 présente une double activité sur la réduction de l'apoptose dépendante de PUMA tout en désactivant l'anti-apoptose médiée par Mcl-1 dans les cellules cancéreuses.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 678158-55-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Mcl1-IN-8 (Comp8) is a Mcl-1-PUMA interface inhibitor, with a Ki of 0.3 μM. Mcl1-IN-8 (Comp8) exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells[1].
[1]. Liu J, et al. Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound. Oncotarget. 2017 Apr 20;8(33):54236-54242.
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *